Incremental risk of high-grade adverse events with immune checkpoint inhibitors with or without poly(adenosine diphosphate-ribose) polymerase inhibitors in first-line treatment of advanced endometrial cancer: a systematic review and meta-analysis.
OBJECTIVE: To evaluate the incremental risk of adverse events associated with immune checkpoint inhibitors, with or without poly(adenosine diphosphate-ribose) polymerase inhibitors, when added to first-line platinum-based chemotherapy for advanced or recurrent endometrial cancer. In the absence of validated predictive biomarkers or a demonstrated overall survival benefit, poly(adenosine diphosphate-ribose) polymerase inhibitor-based treatment intensification should be individualized and carefully weighed against its additional toxicity burden.
OBJECTIVE: To evaluate the incremental risk of adverse events associated with immune checkpoint inhibitors, with or without poly(adenosine diphosphate-ribose) polymerase inhibitors, when added to first-line platinum-based chemotherapy for advanced or recurrent endometrial cancer. In the absence of validated predictive biomarkers or a demonstrated overall survival benefit, poly(adenosine diphosphate-ribose) polymerase inhibitor-based treatment intensification should be individualized and carefully weighed against its additional toxicity burden.
What the study was
- Study design
- Meta-Analysis
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Int J Gynecol Cancer
Why it surfaced
Matched watchlist topic(s): Novel therapeutics: immunotherapy, CAR-T, targeted therapy. Study design: Meta-Analysis. Score 9/10. 🟢 Near-term implementable finding.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.